OGUMA YasuoKindai University Nara Hospital Lecturer in Medical School | |||
Last Updated :2024/04/25
Researcher Information
Degree
J-Global ID
Research Areas
Academic & Professional Experience
- 2023/04 - Today Kindai UniversityFaculty of Medicine医学部講師
- 2022/04 - 2023/03 Kindai UniversityFaculty of Medicine医学部助教A
- 2021/10 - 2022/03 宝塚市立病院放射線治療科医長
- 2021/04 - 2021/09 Kindai University医学部医学科医学部助教A
- 2020/04 - 2021/03 Kindai UniversityFaculty of Medicine医学部助教A
- 2019/04 - 2020/03 Kindai University医学部医学科医学部助教A
- 2015/04 - 2019/03 Kindai UniversityFaculty of Medicine医学部助教B
- 2013/04 - 2015/03 Nara hospital Kindai Universityjunior resident
- 2002/04 - 2008/09 西日本旅客鉄道株式会社
Association Memberships
Published Papers
- yasuo oguma; Makoto Hosono; Kaoru Okajima; Eri Inoue; Kiyoshi Nakamatsu; Hiroshi Doi; Tomohiro Matsuura; Masahiro Inada; Takuya Uehara; Yutaro Wada; Aritoshi Ri; Yutaka Yamamoto; Kazuhiro Yoshimura; Hirotsugu Uemura; Yasumasa NishimuraRadiation 2022/09
- Eri Inoue; Kaoru Okajima; Hiroshi Doi; Kouhei Fukuda; Yasuo Oguma; Aritoshi Ri; Daisuke Nishikawa; Katsunari Yane; Tomohiro Matsuura; Yasumasa NishimuraActa Oto-Laryngologica Informa UK Limited 141 (11) 1022 - 1026 0001-6489 2021/11 [Refereed]
BACKGROUND: Hypothyroidism is a common adverse event after radiotherapy for head and neck tumors and the incidence need to be re-evaluated because of using intensity-modulated radiotherapy (IMRT). AIMS/OBJECTIVES: Confirm the dose-volume effect of IMRT for pharyngeal cancer on hypothyroidism. MATERIALS AND METHODS: This was a retrospective analysis of patients underwent IMRT for pharyngeal cancer from June 2011 to May 2018. Patients were classified into group A (thyroid stimulating hormone (TSH) <5μU/ml), group B (5< =TSH < 10), and group C (10< =TSH) based on TSH over 36 months post-radiation. Radiation dose, thyroid volume, and the proportion of the thyroid that received X Gy or greater (Vx) were measured. RESULTS: Fifty-two patients were included in this work. Hypothyroidism developed in 33/52 (63%) patients, 13 in group B and 20 in group C. The mean radiation dose to the thyroid was 49.4 Gy and the median time until hypothyroidism was 39 months after irradiation. Hypothyroidism was significantly related to neck dissection (ND) and radiation dose to the thyroid. Patients whose thyroid received 45 Gy or more (V45) >67% had a significantly higher incidence of hypothyroidism. CONCLUSIONS AND SIGNIFICANCE: Patients with pharyngeal cancer who had ND and V45 to the thyroid >67% are at risk of hypothyroidism. - Takuya Uehara; Hiroshi Doi; Kazuki Ishikawa; Masahiro Inada; Saori Tatsuno; Yutaro Wada; Yasuo Oguma; Hisato Kawakami; Kiyoshi Nakamatsu; Makoto Hosono; Yasumasa NishimuraHead & Neck Wiley 43 (10) 3132 - 3141 1043-3074 2021/07 [Refereed]
BACKGROUND: The present study aimed to evaluate the prognostic factors in human papillomavirus (HPV)-positive and HPV-negative oropharyngeal cancer (OPC) treated with definitive radiotherapy. METHODS: We retrospectively evaluated 101 patients with OPC who underwent definitive radiotherapy between 2008 and 2018. RESULTS: The median follow-up period of the surviving patients was 68 months (range, 8-164 months). The 5-year overall survival rate was 69.8%. Univariate analyses revealed that poor survival was associated with male sex, smoking ≥30 pack-years, Eastern Cooperative Oncology Group performance status ≥1, tumor-node-metastasis (TNM) stage III-IV (8th edition), HPV-negativity, serum lactate dehydrogenase (LDH) ≥202, C-reactive protein/albumin ratio ≥0.15, and lymphocyte-to-monocyte ratio <2.90. In multivariate analyses, poor survival was independently correlated with smoking ≥30 pack-years (p < 0.01) and LDH ≥202 (p = 0.02). CONCLUSIONS: The present study suggested that high LDH levels predicted poor survival after definitive radiotherapy for patients with both HPV-positive and HPV-negative OPC. - Masahiro Inada; Yasumasa Nishimura; Kazuki Ishikawa; Takuya Uehara; Yutaro Wada; Yasuo Oguma; Hiroshi Doi; Kiyoshi NakamatsuEsophagus Springer Science and Business Media LLC 18 (3) 638 - 644 1612-9059 2021/07 [Refereed]
BACKGROUND: The role of intensity-modulated radiation therapy in the treatment of cervical esophageal cancer remains unclear. The outcome of concurrent chemoradiotherapy for cervical esophageal squamous cell carcinoma using intensity-modulated radiation therapy was retrospectively evaluated. METHODS: Between 2004 and 2017, 36 patients with cervical esophageal cancer treated with intensity-modulated radiation therapy were included. Among these patients, one had stage II disease, three stage III, 19 stage IVA, and 13 stage IVB. All patients received radiotherapy at a dose of 60 Gy and concurrent platinum-based doublet chemotherapy. RESULTS: The median follow-up period for surviving patients was 36 months. Three-year locoregional control, progression-free survival, and overall survival rates were 54, 40, and 46%, respectively. Disease progression was noted in 20 out of 36 patients (56%). Grade 3 late toxicities were observed in four patients (three esophageal stenoses and one carotid artery stenosis). There were no grade 4-5 toxicities. Univariate analysis identified the duration of radiotherapy as a prognostic factor for overall survival. CONCLUSIONS: Chemoradiotherapy using intensity-modulated radiation therapy for locally advanced cervical esophageal carcinoma achieved satisfactory locoregional control and survival with acceptable toxicities. - 超高齢者の有棘細胞癌に対して放射線治療を選択した症例大原 裕士郎; 西崎 絵理奈; 細本 宜志; 山本 容子; 吉岡 希; 磯貝 理恵子; 山田 秀和; 和田 祐太郎; 大熊 康央; 福田 浩平; 岡嶋 肇日本皮膚科学会雑誌 (公社)日本皮膚科学会 130 (1) 110 - 110 0021-499X 2020/01